Abeona therapeutics® enters into agreement to sell priority review voucher for $155 million

Cleveland, may 12, 2025 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced it has entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher (prv) for gross proceeds of $155 million upon the closing of the transaction. abeona was awarded the prv following the u.s. food and drug administration (fda) approval of zevaskyn™ (prademagene zamikeracel) on april 28, 2025.
ABEO Ratings Summary
ABEO Quant Ranking